We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Corient Private Wealth
151
Corient Private Wealth
Florida
$4.31M +$1.8M +49,754 +69%
RAM
152
Resona Asset Management
Japan
$4.04M +$145K +4,006 +4%
SLAM
153
Swiss Life Asset Management
$4.03M +$4.14M +114,257 New
MWM
154
Moran Wealth Management
Florida
$4.01M +$1.06M +29,231 +35%
YIH
155
Y-Intercept (HK)
Hong Kong
$3.95M -$1.38M -37,988 -25%
ASRS
156
Arizona State Retirement System
Arizona
$3.95M +$160K +4,411 +4%
Bank of Montreal
157
Bank of Montreal
Ontario, Canada
$3.88M -$436K -12,057 -10%
SEI Investments
158
SEI Investments
Pennsylvania
$3.87M +$232K +6,403 +6%
RIA
159
Regal Investment Advisors
Michigan
$3.87M +$608K +16,792 +18%
Kovitz Investment Group Partners
160
Kovitz Investment Group Partners
Illinois
$3.87M -$157K -4,338 -4%
LPL Financial
161
LPL Financial
California
$3.8M +$1.98M +54,650 +103%
PCA
162
Pallas Capital Advisors
Massachusetts
$3.69M +$48.5K +1,341 +1%
WSFS
163
Wilmington Savings Fund Society
Delaware
$3.68M -$112K -3,080 -3%
EP
164
Edgestream Partners
New Jersey
$3.56M +$3.65M +100,960 New
American Century Companies
165
American Century Companies
Missouri
$3.54M +$290K +8,011 +9%
PCP
166
Pacific Capital Partners
$3.53M +$90.5K +2,500 +3%
Zurich Cantonal Bank
167
Zurich Cantonal Bank
Switzerland
$3.49M -$461K -12,732 -11%
Teacher Retirement System of Texas
168
Teacher Retirement System of Texas
Texas
$3.45M -$194K -5,362 -5%
HA
169
Heartland Advisors
Wisconsin
$3.41M +$3.5M +96,553 New
WG
170
Winton Group
United Kingdom
$3.36M +$3.45M +95,200 New
MSFS
171
Main Street Financial Solutions
Pennsylvania
$3.36M -$606K -16,740 -15%
LAM
172
L2 Asset Management
Massachusetts
$3.25M +$3.09M +85,459 +1,265%
AM
173
AGF Management
Ontario, Canada
$3.22M -$70.6K -1,950 -2%
CP
174
CenterBook Partners
Connecticut
$3.12M -$2.56M -70,706 -44%
OA
175
Oxbow Advisors
Texas
$2.99M +$3.07M +84,741 New
5 6
7
8 9

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.